|
GB2213058B
(en)
*
|
1987-12-03 |
1991-07-17 |
Reckitt & Colmann Prod Ltd |
Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
|
|
GB8728294D0
(en)
*
|
1987-12-03 |
1988-01-06 |
Reckitt & Colmann Prod Ltd |
Treatment compositions
|
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
|
US5272149A
(en)
*
|
1992-05-05 |
1993-12-21 |
Stalling Reginald W |
Symptom controlled receptor substitution for addiction withdrawl
|
|
US6096756A
(en)
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
|
DE19652188C2
(de)
*
|
1996-12-16 |
2002-02-14 |
Lohmann Therapie Syst Lts |
Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
|
|
US5968547A
(en)
*
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
|
US7220737B1
(en)
|
1997-09-04 |
2007-05-22 |
Novoneuron, Inc |
Noribogaine in the treatment of pain and drug addiction
|
|
EP1327447B1
(en)
*
|
1997-09-04 |
2011-05-25 |
Novoneuron, Inc. |
Noribogaine in the treatment of pain and drug addiction
|
|
DK2266564T3
(da)
*
|
1997-12-22 |
2013-06-03 |
Euro Celtique Sa |
Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og en opioidantagonist
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
KR100417490B1
(ko)
*
|
1997-12-22 |
2004-02-05 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 제형의 남용을 방지하는 방법
|
|
WO1999041599A1
(fr)
*
|
1998-02-16 |
1999-08-19 |
The Institute Of Physical And Chemical Research |
Cassette capillaire et procede de production correspondant
|
|
US6007841A
(en)
*
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
US6849263B2
(en)
*
|
1998-12-21 |
2005-02-01 |
Generex Pharmaceutical Incorporated |
Pharmaceutical compositions for buccal delivery of pain relief medications
|
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
|
AU765496C
(en)
*
|
1999-08-27 |
2005-08-25 |
Brookwood Pharmaceuticals Inc. |
Injectable buprenorphine microparticle compositions and their use
|
|
RU2147880C1
(ru)
*
|
1999-11-10 |
2000-04-27 |
Мамренко Валерий Русланович |
Лекарственное средство для лечения пациентов с хроническим алкоголизмом и способ их лечения
|
|
AR031682A1
(es)
*
|
1999-11-19 |
2003-10-01 |
Reckitt Benckiser Helthcare Uk |
Composiciones farmaceuticas
|
|
EA004876B1
(ru)
*
|
2000-02-08 |
2004-08-26 |
Эро-Селтик, С.А. |
Устойчивые к порче композиции опиоидных агонистов для перорального введения
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
|
US20030035839A1
(en)
*
|
2001-05-15 |
2003-02-20 |
Peirce Management, Llc |
Pharmaceutical composition for both intraoral and oral administration
|
|
US20030022909A1
(en)
*
|
2001-06-05 |
2003-01-30 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
|
BR0205721A
(pt)
*
|
2001-07-06 |
2003-09-30 |
Endo Pharmaceuticals Inc |
Formulações de oximorfona de liberação controlada
|
|
EP1404331B1
(en)
*
|
2001-07-06 |
2007-10-31 |
Penwest Pharmaceuticals Co. |
Sustained release formulations of oxymorphone
|
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
|
ATE419039T1
(de)
*
|
2001-07-18 |
2009-01-15 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
IS7142A
(is)
|
2001-08-06 |
2004-02-05 |
Euroceltique S.A. |
Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
|
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
AU2002337686B2
(en)
*
|
2001-09-26 |
2008-05-15 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
|
US6863901B2
(en)
*
|
2001-11-30 |
2005-03-08 |
Collegium Pharmaceutical, Inc. |
Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
|
|
US6827946B2
(en)
*
|
2001-12-05 |
2004-12-07 |
Collegium Pharmaceutical, Inc. |
Compositions containing both sedative and non-sedative antihistamines
|
|
CA2478523A1
(en)
|
2002-04-05 |
2003-10-16 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
|
PT2561860T
(pt)
*
|
2002-05-31 |
2018-05-08 |
Titan Pharmaceuticals Inc |
Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
|
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
|
DE602004024963D1
(de)
*
|
2003-03-13 |
2010-02-25 |
Controlled Chemicals Inc |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
|
US20050031667A1
(en)
*
|
2003-03-31 |
2005-02-10 |
Patel Rajesh A. |
Implantable polymeric device for sustained release of dopamine agonist
|
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
CA2569958C
(en)
|
2004-06-12 |
2016-03-22 |
Jane C. Hirsh |
Abuse-deterrent drug formulations
|
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
US7568409B2
(en)
*
|
2005-03-30 |
2009-08-04 |
Federal-Mogul World Wide, Inc |
Hybrid orbiting spindle for shaping non-circular holes
|
|
FR2898056B1
(fr)
|
2006-03-01 |
2012-01-20 |
Ethypharm Sa |
Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
|
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
|
JP5566102B2
(ja)
*
|
2006-06-19 |
2014-08-06 |
アルファーマ ファーマシューティカルズ エルエルシー |
医薬組成物
|
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
|
PL2101740T3
(pl)
|
2006-12-04 |
2014-04-30 |
Orexo Ab |
Nowa, niepodatna na nadużycie kompozycja farmaceutyczna zawierająca opioidy
|
|
US20080199407A1
(en)
|
2007-02-15 |
2008-08-21 |
Slater Kenneth C |
Drug Detoxification Protocol Using Microdosing
|
|
US20080207593A1
(en)
*
|
2007-02-28 |
2008-08-28 |
Collegium Pharmaceutical, Inc. |
Antihistamine Combination
|
|
GB2447014A
(en)
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
|
WO2009088673A2
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
ES2635733T3
(es)
*
|
2008-07-07 |
2017-10-04 |
Euro-Celtique S.A. |
Uso de antagonistas opioideos para tratar la retención urinaria
|
|
ES2706407T3
(es)
|
2009-03-10 |
2019-03-28 |
Euro Celtique Sa |
Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
|
|
US8475832B2
(en)
|
2009-08-07 |
2013-07-02 |
Rb Pharmaceuticals Limited |
Sublingual and buccal film compositions
|
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
|
RU2586296C2
(ru)
|
2010-07-23 |
2016-06-10 |
Демеркс, Инк. |
Композиции норибогаина
|
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
|
SG2014009401A
(en)
|
2011-09-19 |
2014-05-29 |
Orexo Ab |
New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
|
|
JP2015500833A
(ja)
|
2011-12-09 |
2015-01-08 |
デメレックス， インコーポレイテッド |
ノルイボガインのリン酸エステル
|
|
US9211293B2
(en)
*
|
2011-12-15 |
2015-12-15 |
Alkermes Pharma Ireland Limited |
Opioid agonist antagonist combinations
|
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
|
EP2807168A4
(en)
|
2012-01-25 |
2015-10-14 |
Demerx Inc |
SYNTHETIC VOACANGINE
|
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
|
EP2934541A4
(en)
|
2012-12-20 |
2016-08-03 |
Demerx Inc |
NORIBOGAINE SUBSTITUTE
|
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
US9550789B2
(en)
|
2014-06-18 |
2017-01-24 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
|
CA2998147A1
(en)
*
|
2015-09-09 |
2017-03-16 |
Biodelivery Sciences International, Inc. |
Methods of safely transitioning a subject to buprenorphine
|
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
|
CA3082892A1
(en)
|
2017-11-15 |
2019-05-23 |
The Regents Of The University Of California |
Treatment of opioid use disorder, opioid withdrawal symptoms and chronic pain
|